Budget impact analysis of Jivi ® (damoctocog alfa pegol, BAY 94-9027) in severe Hemophilia A in Japan.

CONCLUSIONS: BAY 94-9027 can reduce total severe HA treatment costs, driven by lower annual rFVIII utilization, and a narrow weekly dosing range compared to competitor products in the Japanese market. PMID: 33459088 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research